|Jess B. Rabourn, CFA | Chief Executive Officer
In 2011 Jess and his advisory team created PCUT BioPartners, Inc. to launch commercial drug development ventures in diseases with unmet medical need. The team believes it can lower the barriers to bringing existing products through proof of concept (PoC) clinical trial in this difficult space.
Jess is a trained institutional investor with substantial experience with quantitative risk models and portfolio analytics. His 18 year finance career includes work at Morgan Stanley, Thomson Financial, and Allianz Global Investors (AGI). He has portfolio management experience in equity and fixed income, and he covered macro-economic and volatility arbitrage strategies at AGI’s hedge fund platform.
Mr. Rabourn has undergraduate degrees in Economics and in German from University of California Davis, and he earned the Chartered Financial Analyst designation in 2004. He plans to complete the Biotechnology certificate program at University of California Extension in 2012.
|Candida Fratazzi, MD | Chief Medical Officer
Candida is a clinical strategy and trial design specialist with more than 25 years of research experience. Her work led to market approval of Velaglucerase alpha (Shire), Replagal (Shire), Lipoprotamase (Alnara), and Tigecycline (Wyeth). She is a recognized expert in the development of orphan indications and rare diseases clinical designs. Dr. Fratazzi founded Boston Biotech Clinical Research (BBCR), LLC in 2009. Prior to devoting her time, within BBCR, to boutique consulting to small and medium sized biotech working in specialty clinical trials, she had served as senior medical leader at Altus, Shire HGT, Johnson & Johnson and Wyeth.
Dr. Fratazzi has also devoted special attention to drug safety signaling, risk management, and launched the initiative of the independent Drug Safety Monitoring Board (DSMB). She served on the faculties of Harvard and John Hopkins Universities and Imperial College (UK). She has co-authored more than 50 scientific papers in peer reviewed journals and book chapters. Currently, she is a reviewer for specialized journals including Biologics, Target & Therapy, Biosimilars, Drug Design, Development and Therapy, Clinical Intervention in Aging.
Dr. Fratazzi will be the medical supervisor for PCUT Bio’s clinical development programs, including protocol design and authority over PCUT Bio’s related conduct and reporting.
|Jamie Stewart, Esq. | Chief Operating Officer and General Counsel
Jamie is an attorney with significant experience working with emerging technology companies. While a corporate attorney at prestigious Silicon Valley law firms, he specialized in working with technology companies throughout their life cycles, from incorporation through venture financing through mergers, acquisitions, and IPOs. Mr. Stewart has also worked as the General Counsel of a technology company where he helped direct internal operations and oversaw a company merger.
Prior to his work in Silicon Valley, Mr. Stewart was employed at major international law firms in New York where he specialized in working with large investment banks and institutional investors to structure and document complex structured finance transactions.
Mr. Stewart graduated summa cum laude from Whitman College and earned a J.D. from Yale Law School.